# Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

> **NCT00896532** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 419 (actual)

## Conditions studied

- Low Bone Mineral Density
- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Placebo to Romosozumab
- **DRUG:** Alendronate
- **DRUG:** Teriparatide
- **DRUG:** Romosozumab
- **DRUG:** Denosumab
- **DRUG:** Placebo to Denosumab
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00896532
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-03
- **Primary completion:** 2011-02-21
- **Final completion:** 2016-02-18
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2022-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896532, "Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00896532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*